Common Shares, no par value
- Symbol
- BHVN
- Exchange
- NYSE
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Biohaven Ltd.
BHVNNYSEEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On March 2, 2026, Biohaven Ltd. (the “Registrant”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2025. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference. In accordance with General Instruction B.2.…
Press release in this filing
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results →Company context
Biohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, obesity, neuroscience, and oncology. The Company is advancing its innovative portfolio of therapeutics, leveraging its proven drug development experience and multiple proprietary drug development platforms. Biohaven's extensive clinical and preclinical programs include Kv7 ion channel modulation for epilepsy; MoDE and TRAP extracellular protein degradation for immunological diseases; and myostatin inhibition for neuromuscular and metabolic diseases, including obesity.
Current securities
Registered securities in this filing
Biohaven Ltd. · 8-K · Filed 2026-03-02
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition.
On March 2, 2026, Biohaven Ltd. (the “Registrant”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2025. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.
Filed exhibits (1)
EX-99.1 2 a2025q4bhvnearningsprex991.htm EX-99.1 Document Exhibit 99.1 Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results • Prioritizing three key, late-stage clinical programs including Molecular Degrader of Extracellular Proteins (MoDE™) and Targeted Removal of Aberrant Protein (TRAP™) extracellular protein degradation for immunological diseases, Kv7 ion channel modulation for epilepsy; and myostatin-activin pathway targeting obesity: ◦ Inflammation and Immunology: ▪ Graves' Disease: First-in-patient clinical experience with IgG MoDE degrader BHV-1300 resulted in complete suppression of disease-causing TSH receptor-stimulating antibodies, normalization of previously elevated thyroid hormones within weeks after dosing a patient with Graves' disease. BHV-1300 has shown the potential for best-in-class reductions of IgG, with maximum reductions of up to an 87% decrease from baseline within weeks of dosing in a study conducted in healthy volunteers. The Company intends to initiate a pivotal study with BHV-1300 in Graves' disease in the second half of 2026. ▪ IgA Nephropathy (IgAN): First dosing of BHV-1400 TRAP degrader in I…
Open exhibit ↗